-
Mashup Score: 18
Long term PFS results are presented at ASCO 2024, but the trial had a suboptimal control arm.
Source: www.drugdevletter.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 1The Drug Development Letter | Vinay Prasad | Substack - 6 month(s) ago
We cover all aspects of pharmaceutical drug development; early, late phase and FDA pivotal trials; Focus on oncology, but also cover important cardiology, neurology and drugs for rare diseases. Click to read The Drug Development Letter, by Vinay Prasad, a Substack publication with thousands of subscribers.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
RT @pharmatinib: Check out our latest post on https://t.co/iCAC40k5ik @Timothee_MD @VPrasadMDMPH "While most discussions of the shortage c…
-
-
Mashup Score: 1The Drug Development Letter | Vinay Prasad | Substack - 6 month(s) ago
We cover all aspects of pharmaceutical drug development; early, late phase and FDA pivotal trials; Focus on oncology, but also cover important cardiology, neurology and drugs for rare diseases. Click to read The Drug Development Letter, by Vinay Prasad, a Substack publication with thousands of subscribers.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
RT @pharmatinib: Check out our latest post on https://t.co/iCAC40k5ik @Timothee_MD @VPrasadMDMPH "While most discussions of the shortage c…
-
-
Mashup Score: 1The Drug Development Letter | Vinay Prasad | Substack - 6 month(s) ago
We cover all aspects of pharmaceutical drug development; early, late phase and FDA pivotal trials; Focus on oncology, but also cover important cardiology, neurology and drugs for rare diseases. Click to read The Drug Development Letter, by Vinay Prasad, a Substack publication with thousands of subscribers.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
RT @pharmatinib: Check out our latest post on https://t.co/iCAC40k5ik @Timothee_MD @VPrasadMDMPH "While most discussions of the shortage c…
-
-
Mashup Score: 1The Drug Development Letter | Vinay Prasad | Substack - 6 month(s) ago
We cover all aspects of pharmaceutical drug development; early, late phase and FDA pivotal trials; Focus on oncology, but also cover important cardiology, neurology and drugs for rare diseases. Click to read The Drug Development Letter, by Vinay Prasad, a Substack publication with thousands of subscribers.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
RT @pharmatinib: Check out our latest post on https://t.co/iCAC40k5ik @Timothee_MD @VPrasadMDMPH "While most discussions of the shortage c…
-
-
Mashup Score: 3
When different censoring rules shape different trial results, there is a problem.
Source: www.drugdevletter.comCategories: General Medicine News, General HCPsTweet-
@US_FDA 's censoring rules doubled the PFS difference, how is this possible? When different censoring rules shape different trial results, there is a problem. https://t.co/xX3Jm3CpPG via @VPrasadMDMPH https://t.co/d5kR3YysuY
-
-
Mashup Score: 333HOW TO DO A GREAT ONCOLOGY JOURNAL CLUB... LIVE EDITION! + Q&A - 6 month(s) ago
I recorded this video with my research team ! Hope you will enjoy it !
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
How to present journal club 10 questions I ask when I read and interpret a cancer clinical trial! Full video on The Drug Development Letter Subscribe now for FREE @Timothee_MD https://t.co/OO11BQbg86 https://t.co/HcfP0VTuXp
-
-
Mashup Score: 14
E1193, an intergroup trial led by George Sledge, with survival results driving the main conclusions of the study.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
Really great post on today's Drug Development Letter Sign up for free for industry insights https://t.co/UY79VuUXIl https://t.co/z1jPB4ph3m
-
-
Mashup Score: 5
E1193, an intergroup trial led by George Sledge, with survival results driving the main conclusions of the study.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
On revealed preferences by @VPrasadMDMPH @Timothee_MD Doublet chemo in breast cancer improves RR and TTF! The new SOC!!! But no one does this… 💎 + chemo improves RR and TTF and the academic response is 👏👏 Well… why no doublet??? https://t.co/2W2drqGCHT
-
-
Mashup Score: 18What to expect from the LAURA trial presentation at ASCO-2024? (a PFS benefit? take it for granted) - 6 month(s) ago
Osimertinib “maintenance” after chemoradiotherapy in EGFR-mutated unresectable stage III lung cancer.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
Great post in drug dev letter by @Timothee_MD about what to look for in Laura trial #asco24 Strongly worry about these limitations. https://t.co/qLMFL8heAq https://t.co/VsCtax0fxU
-
How the hell did Crown run with an inferior control arm? Alectinib beat Crizo in 2017. @Timothee_MD https://t.co/I1SkFKB9A9 #ASCO24